Faculty Opinions recommendation of Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.

Phase Ii ◽

Phase Ii Trial ◽

Cancer Stage ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB–IV

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.04.050 ◽

2012 ◽

Vol 126 (2) ◽

pp. 236-240 ◽

Cited By ~ 14

Author(s):

Werner Meier ◽

Andreas du Bois ◽

Jörn Rau ◽

Martina Gropp-Meier ◽

Klaus Baumann ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Cancer Stage ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps257 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS257-TPS257 ◽

Cited By ~ 4

Author(s):

J. D. Hainsworth ◽

T. M. Numnum ◽

G. G. Rao

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Stage Iii ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Paclitaxel/carboplatin with or without sorafenib in the first‐line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute

Cancer Medicine ◽

10.1002/cam4.376 ◽

2014 ◽

Vol 4 (5) ◽

pp. 673-681 ◽

Cited By ~ 30

Author(s):

John D. Hainsworth ◽

Dana S. Thompson ◽

John A. Bismayer ◽

Victor G. Gian ◽

William M. Merritt ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Stage Iii ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment ◽

Research Institute

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Dose Dense ◽

Phase II trial of bevacizumab with carboplatin and dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.194 ◽

2015 ◽

Vol 137 ◽

pp. 79

Author(s):

N.D. Fleming ◽

R.L. Coleman ◽

C.S. Tung ◽

M.F. Munsell ◽

A.K. Sood

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Advanced Ovarian Cancer ◽

Line Treatment ◽

First Line ◽

Dose Dense ◽

Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study

International Journal of Gynecological Cancer ◽

10.1046/j.1525-1438.2003.13039.x ◽

2003 ◽

Vol 13 (2) ◽

pp. 130-137 ◽

Cited By ~ 9

Author(s):

T. Bauknecht ◽

A. Hefti ◽

G. Morack ◽

C. Villena-Heinsen ◽

D. Wallwiener ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Cited By ~ 11

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

The Oncologist ◽

10.1634/theoncologist.2017-0640 ◽

2018 ◽

Vol 23 (8) ◽

pp. 919-927 ◽

Cited By ~ 1

Author(s):

Goro Nakayama ◽

Ayako Mitsuma ◽

Yuki Sunagawa ◽

Kiyoshi Ishigure ◽

Hiroyuki Yokoyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Japanese Patients ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Annals of Oncology ◽

10.1093/annonc/mdi047 ◽

2005 ◽

Vol 16 (2) ◽

pp. 282-288 ◽

Cited By ~ 83

Author(s):

M.M. Borner ◽

J. Bernhard ◽

D. Dietrich ◽

R. Popescu ◽

M. Wernli ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial.

10.1158/0008-5472.sabcs11-p5-19-03 ◽

2011 ◽

Cited By ~ 1

Author(s):

WJ Gradishar ◽

D Krasnojon ◽

S Cheporov ◽

AN Makhson ◽

GM Manikhas ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽